Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
biotechnology
-
DXR plays a role in the methyl-D-erythritol 4-phosphate pathway, which is responsible for the biosynthesis of a substantial number of natural compounds of biological and biotechnological importance and is considered as a target to develop new herbicides and antimicrobial drugs
drug development
the enzyme is a potential target for antimalarial drug development and chemotherapy
drug development
-
the enzyme is a target for antibacterial agents and inhibitor design
drug development
-
the enzyme is an excellent drug target in a number of pathogenic organisms
drug development
-
Escherichia coli Dxr represents a valuable model enzyme for the screening for new antimalarial compounds, since work with the Plasmodium falciparum Dxr is associated with considerably high effort due to the instability of this enzyme and the low yield of the available recombinant expression system, no major differences in the IC50 between Escherichia coli Dxr and Plasmodium falciparum Dxr
drug development
-
Escherichia coli Dxr represents a valuable model enzyme for the screening for new antimalarial compounds, since work with the Plasmodium falciparum Dxr is associated with considerably high effort due to the instability of this enzyme and the low yield of the available recombinant expression system, no major differences in the IC50 between Escherichia coli Dxr and Plasmodium falciparum Dxr
drug development
1-deoxy-D-xylulose-5-phosphate reductoisomerase in the nonmevalonate isoprene biosynthesis pathway is a target for developing antimalarial drugs
drug development
-
because the enzyme is absent in humans, DXR is a target for drug discovery
drug development
-
the enzyme is a target for the design of antimalarial drugs
drug development
enzyme DXR is a validated antimicrobial target
drug development
enzyme DXR is an antimicrobial target
drug development
enzyme DXR is an antimicrobial target
drug development
enzyme DXR is an antimicrobial target
drug development
the enzyme from Escherichia coli is a valuable target for the development of antimicrobial compounds
drug development
the enzyme from Mycobacterium smegmatis is a valuable target for the development of antimicrobial compounds
drug development
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
drug development
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
drug development
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
drug development
-
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
-
drug development
-
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
-
drug development
-
the enzyme from Mycobacterium smegmatis is a valuable target for the development of antimicrobial compounds
-
drug development
-
the enzyme is an excellent drug target in a number of pathogenic organisms
-
drug development
-
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
-
drug development
-
enzyme DXR is an antimicrobial target
-
drug development
-
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
-
drug development
-
enzyme DXR is an antimicrobial target
-
medicine
50% inhibition of growth of parasite in cultured infected erythrocytes is 2-3 times lower with fetal bovine serum in the culture liquide than with human serum
medicine
study on inhibitory effect of antimalarial drugs in clinical isolates of Plasmodium falciparum. No correlation between chloroquine or pyrimethamine and fosmidomycin. Fosmidomycin is moderately active against both chloroquine-susceptible and chloroquine-resistant isolates
additional information
the enzyme is a target for development of antibacterial drugs, determination of the antimicrobial activities of various essential oils against different microbials
additional information
-
the enzyme is a target for development of antibacterial drugs, determination of the antimicrobial activities of various essential oils against different microbials